Abstract
Gene-engineered dendritic cells (DC) are being tested in cancer immunotherapy. DC are the best equipped antigen-presenting cells (APC) to overcome tolerance / ignorance to self antigens presented by cancer cells. Genetic immunotherapy with DC engineered to express tumor antigens has the potential advantages of endogenous epitope presentation by both major histocompatibility complex (MHC) class I and II molecules. DC can also be gene-modified to express immunostimulatory molecules that further enhance their antigen-presenting function. Review of the literature provided 52 manuscripts where gene-modified DC were being tested in murine models of immunotherapy for cancer. Review of the antitumor effects of gene-modified DC in these preclinical studies provides valuable information on the optimal methods of gene transfer into DC, the schedule of administration, the route, dose and the underlying immunological mechanisms of the antitumor effects. These data may help in the translation of this promising approach to the clinic.
Keywords: Cancer Immunotherapy, Gene-Modified Dendritic Cells, immunostimulatory molecules, proteasome complex, Viral Vector Transduction, Takayama
Current Gene Therapy
Title: Cancer Immunotherapy Using Gene-Modified Dendritic Cells
Volume: 2 Issue: 1
Author(s): Antoni Ribas, Lisa H. Butterfield, John A. Glaspy and James S. Economou
Affiliation:
Keywords: Cancer Immunotherapy, Gene-Modified Dendritic Cells, immunostimulatory molecules, proteasome complex, Viral Vector Transduction, Takayama
Abstract: Gene-engineered dendritic cells (DC) are being tested in cancer immunotherapy. DC are the best equipped antigen-presenting cells (APC) to overcome tolerance / ignorance to self antigens presented by cancer cells. Genetic immunotherapy with DC engineered to express tumor antigens has the potential advantages of endogenous epitope presentation by both major histocompatibility complex (MHC) class I and II molecules. DC can also be gene-modified to express immunostimulatory molecules that further enhance their antigen-presenting function. Review of the literature provided 52 manuscripts where gene-modified DC were being tested in murine models of immunotherapy for cancer. Review of the antitumor effects of gene-modified DC in these preclinical studies provides valuable information on the optimal methods of gene transfer into DC, the schedule of administration, the route, dose and the underlying immunological mechanisms of the antitumor effects. These data may help in the translation of this promising approach to the clinic.
Export Options
About this article
Cite this article as:
Ribas Antoni, Butterfield H. Lisa, Glaspy A. John and Economou S. James, Cancer Immunotherapy Using Gene-Modified Dendritic Cells, Current Gene Therapy 2002; 2 (1) . https://dx.doi.org/10.2174/1566523023348129
DOI https://dx.doi.org/10.2174/1566523023348129 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Suitable Antibacterial Substances for the Treatment of Urinary Tract Infections
Anti-Infective Agents in Medicinal Chemistry Implications of Nanoscale Based Drug Delivery Systems in Delivery and Targeting Tubulin Binding Agent, Noscapine in Cancer Cells
Current Drug Metabolism Robotic Assisted Surgery in Gynecology: Current Insights and Future Perspectives
Recent Patents on Biotechnology Viral Reservoirs an Impediment to HAART: New Strategies to Eliminate HIV-1
Current Drug Targets - Infectious Disorders Commercial Development and Application of Type A Lantibiotics
Recent Patents on Anti-Infective Drug Discovery Reproductive and Endocrine Effects of p-Nonylphenol and Methoxychlor: A Review
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Model Systems for Pulmonary Infectious Diseases: Paradigms of Anthrax and Tuberculosis
Current Topics in Medicinal Chemistry Applications of Lipid based Formulation Technologies in the Delivery of Biotechnology-based Therapeutics
Current Pharmaceutical Biotechnology Development of Ribonucleotide Reductase Inhibitors: A Review on Structure Activity Relationships
Mini-Reviews in Medicinal Chemistry Current Status of Hormone Replacement Therapy in Post Menopausal Women
Current Drug Therapy Thermostable Subunit Vaccines for Pulmonary Delivery: How Close Are We?
Current Pharmaceutical Design Antibiotic Treatment Strategies for Helicobacter pylori Infection
Recent Patents on Anti-Infective Drug Discovery Anal Cancer: Focus on HIV-Positive Patients in the HAART Era
Current HIV Research Novel Vaginal Drug Delivery Systems: A Review
Current Drug Therapy Discovery of New Biomarkers of Cancer Using Proteomics Technology
Current Cancer Therapy Reviews Application of Radioisotopes in Anti-Fungal Research and Fungal Disease Studies
Current Medicinal Chemistry - Anti-Infective Agents Biotransformation of Endocrine Disrupting Compounds by Selected Phase I and Phase II Enzymes – Formation of Estrogenic and Chemically Reactive Metabolites by Cytochromes P450 and Sulfotransferases
Current Medicinal Chemistry Management of Ovarian Cancer In Younger Women
Reviews on Recent Clinical Trials Phosphodiesterase-5 Inhibitors: Future Perspectives
Current Pharmaceutical Design Survivin Modulators: An Updated Patent Review (2011 - 2015)
Recent Patents on Anti-Cancer Drug Discovery